ARQT Arcutis Biotherapeutics

Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020

Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020

WESTLAKE VILLAGE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, will host a virtual Investor Day on Wednesday, Dec. 9, 2020, from 11:00 - 1:00 p.m. EST. The Company plans to showcase its unique immune-dermatology product development platform and  robust pipeline of novel drug candidates targeting multiple dermatologic indications. Presentations will be given by Arcutis’ Senior Leadership Team in addition to Zoe Diana Draelos, M.D., consulting professor of dermatology, Duke University School of Medicine, Durham, N.C., and an investigator, Dermatology Consulting Services, High Point, N.C.

A link to register for the event is available . A live audio webcast and archived replay of the presentation will be available in the section of the Arcutis website.

About Arcutis - Bioscience, applied to the skin.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit or follow the company on and .

Investor Contact:

Heather Rowe Armstrong

Vice President, Investor Relations & Corporate Communications



805-418-5006, Ext. 740



EN
02/12/2020

Underlying

ARQTArcutis Biotherapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcutis Biotherapeutics

 PRESS RELEASE
Free
ARQT Arcutis Biother...

Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Ur...

Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflam...

1h / 47m 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,000 restricted stock units of Arcutis’ common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of Februar...

February 5, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase...

Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis 58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with no new safety signals identified through 4 weeks of treatmentAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis deve...

February 2, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agree...

Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America, Inc. mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE® (roflumilast) by Kowa to primary care physicians and pediatricians in the United States. Following the termination, A...

January 26, 2026 1 EN
 PRESS RELEASE
Free
ARQT Arcutis Biother...

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results ...

Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financi...

January 22, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch